September
Proposed Amendment: Temporary Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I (PDF) (September 17, 2024)
George D. Gowder, III, M.D.; Decision and Order (PDF) (September 17, 2024)
Chemtos, LLC (PDF) (September 17, 2024)
Eli-Elsohly Laboratories (PDF) (September 17, 2024)
Mary A. Vreeke, M.D.; Decision and Order (PDF) (September 16, 2024)
Awesome Care Pharmacy, Inc.; Decision and Order (PDF) (September 16, 2024)
Purisys, LLC (PDF) (September 16, 2024)
Bright Green Corporation (PDF) (September 6, 2024)
Biopharmaceutical Research Company (PDF) (September 6, 2024)
Cambridge Isotope Laboratories, Inc. (PDF) (September 6, 2024)
Final Order: Adjustment to the Aggregate Production Quota for Lisdexamfetamine and d-Amphetamine (for Conversion) for 2024 (PDF) (September 5, 2024)
Samirkumar Shah, M.D.; Decision and Order (PDF) (September 4, 2024)
Chattem Chemicals (PDF) (September 4, 2024)
Bright Green Corporation (PDF) (September 4, 2024)
Continuus Pharmaceuticals (PDF) (September 4, 2024)
Catalent CTS, LLC (PDF) (September 4, 2024)
Benuvia Operations, LLC (PDF) (September 4, 2024)
Indivior Inc. (PDF) (September 4, 2024)
Amneal Complex Products Research LLC (PDF) (September 4, 2024)
Chattem Chemicals, Inc. (PDF) (September 4, 2024)
Biopharmaceutical Research Company (PDF) (September 4, 2024)
Cambridge Isotope Laboratories, Inc. (PDF) (September 4, 2024)
Fisher Clinical Services, Inc. (PDF) (September 4, 2024)
Caligor Coghlan Pharma Services (PDF) (September 4, 2024)
Cambrex High Point, Inc (PDF) (September 4, 2024)
Stephen McCarthy, P.A.; Decision and Order (PDF) (September 3, 2024)
August
Proposed Rule: Rescheduling of Marijuana (PDF) (August 29, 2024)
60-Day Notice: Exempt Chemical Preparations Under the Controlled Substance Act (PDF) (August 23, 2024)
Final Rule: Placement of Zuranolone in Schedule IV (PDF) (August 14, 2024)
Robert Rowen, M.D.; Decision and Order (PDF) (August 14, 2024)
Irene Kimura, M.D.; Decision and Order (PDF) (August 14, 2024)
Thomas M. Fausset, O.D.; Decision and Order (PDF) (August 14, 2024)
Michael L. Brodie, M.D.; Decision and Order (PDF) (August 14, 2024)
Stephen Matthews, M.D.; Decision and Order (PDF) (August 9, 2024)
Experic LLC (PDF) (August 8, 2024)
Cambrex High Point, Inc. (PDF) (August 8, 2024)
AMPAC Fine Chemicals, LLC (PDF) (August 8, 2024)
Cambrex Charles City (PDF) (August 8, 2024)
Catalent Greenville, Inc. (PDF) (August 8, 2024)
Benuvia Operations, LLC (PDF) (August 8, 2024)
VICI Health Sciences, LLC (PDF) (August 8, 2024)
Cerilliant Corporation (PDF) (August 8, 2024)
July
Temporary Scheduling Order: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I (PDF) (July 29, 2024)
Galephar Pharmaceutical Research Inc. (PDF) (July 29, 2024)
Catalent Pharma Solutions, LLC (PDF) (July 29, 2024)
Cerilliant Corporation (PDF) (July 29, 2024)
Deron Kovac, DMD; Decision and Order (PDF) (July 24, 2024)
Donna Winingham, MD; Decision and Order (PDF) (July 24, 2024)
Carrie L. Madej, DO; Decision and Order (PDF) (July 24, 2024)
John Qian, MD; Decision and Order (PDF) (July 24, 2024)
60-Day Notice; Extension: Drug Use Statement (PDF) (July 19, 2024)
Curia Missouri Inc. (PDF) (July 8, 2024)
S&B Pharma LLC DBA Norac Pharma (PDF) (July 8, 2024)
Arizona Department of Corrections (PDF) (July 8, 2024)
June
Michael Gore, P.A.; Decision and Order (PDF) (June 28, 2024)
Lisa Jones, N.P.; Decision and Order (PDF) (June 28, 2024)
Jeffrey Pollock, P.A.; Decision and Order (PDF) (June 28, 2024)
Abdul Naushad, M.D.; Decision and Order (PDF) (June 28, 2024)
Arash M. Padidar, M.D.; Decision and Order (PDF) (June 28, 2024)
AndersonBrecon Inc. DBA PCI Pharma Services (PDF) (June 17, 2024)
Lily's Eden Garden Farms Corporation (PDF) (June 17, 2024)
Coconut Grove Pharmacy; Decision and Order (PDF) (June 13, 2024)
American Radiolabeled Chem (PDF) (June 7, 2024)
Usona Institute (PDF) (June 7, 2024)
Veranova, L.P. (PDF) (June 7, 2024)
Unither Manufacturing LLC (PDF) (June 7, 2024)
May
ANI Pharmaceuticals, Inc. (PDF) (May 31, 2024)
Royal Emerald Pharmaceuticals (PDF) (May 31, 2024)
United States Pharmacopeial Convention (PDF) (May 31, 2024)
Revvity, Inc. (PDF) (May 30, 2024)
Almac Clinical Services Incorporate (PDF) (May 30, 2024)
Vici Health Sciences, LLC (PDF) (May 30, 2024)
VA Cooperative Studies Program (PDF) (May 30, 2024)
Royal Emerald Pharmaceuticals (PDF) (May 30, 2024)
Quagen Pharmaceuticals LLC (PDF) (May 30, 2024)
Veranova, L.P. (PDF) (May 30, 2024)
ANI Pharmaceuticals Inc. (PDF) (May 30, 2024)
Chemtos, LLC (PDF) (May 30, 2024)
AMPAC Fine Chemicals Virginia LLC (PDF) (May 30, 2024)
Skalar Pharma, LLC (PDF) (May 30, 2024)
Pharmaron Manufacturing Services (US) LLC; Correction (PDF) (May 29, 2024)
Proposed Rule: Rescheduling of Marijuana (PDF) (May 21, 2024)
Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (May 15, 2024)
Curia New York, Inc. (PDF) (May 9, 2024)
Veranova, L.P. (PDF) (May 9, 2024)
Wedgewood Village Pharmacy, LLC (PDF) (May 8, 2024)
Pisgah Laboratories Inc. (PDF) (May 6, 2024)
Entheogen Pharmaceuticals Inc. (PDF) (May 6, 2024)
Lipomed (PDF) (May 6, 2024)
Research Triangle Institute (PDF) (May 6, 2024)
Restek Corporation (PDF) (May 6, 2024)
NSI Lab Solutions, Inc. (PDF) (May 6, 2024)
AndersonBrecon dba PCI Pharma Services; Correction (PDF) (May 6, 2024)
Pharmaron Manufacturing Services (US) LLC (PDF) (May 6, 2024)
AndersonBrecon dba PCI Pharma Services (PDF) (May 6, 2024)
April
DEA's 2nd Annual Supply Chain Conference (April 30 - May 2, 2024)
Final Order: Placement of Etodesnitazene, N-Pyrrolidino Etonitazene, and Protonitazene in Schedule I (PDF) (April 11, 2024)
Proposed Rule: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I (PDF) (April 11, 2024)
Temporary Rule: Extension of Temporary Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I of the Controlled Substances Act (PDF) (April 11, 2024)
Announcement of Hearing: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I (PDF) (April 9, 2024)
VHG Labs dba LGC Standards (PDF) (April 9, 2024)
Lyndra Therapeutics (PDF) (April 9, 2024)
Traesa A. Brown, M.D.; Decision and Order (PDF) (April 5, 2024)
Ralph Reach, M.D.; Decision And Order (PDF) (April 5, 2024)
Sterling Wisconsin, LLC (PDF) (April 4, 2024)
Patheon Pharmaceuticals Inc. (PDF) (April 4, 2024)
Lonza Tampa, LLC (PDF) (April 4, 2024)
Benuvia Operations, LLC (PDF) (April 4, 2024)
Research Triangle Institute (PDF) (April 3, 2024)
Purisys, LLC (PDF) (April 3, 2024)
30-Day Notice: Drug Use Statement (PDF) (April 2, 2024)
March
Caligor Coghlan Pharma Services (PDF) (March 25, 2024)
Hybrid Pharma (PDF) (March 25, 2024)
Purisys, LLC (PDF) (March 25, 2024)
Stepan Company (PDF) (March 25, 2024)
SpecGx LLC (PDF) (March 25, 2024)
Restek Corporation (PDF) (March 25, 2024)
Halo Pharmaceutical Inc. (PDF) (March 25, 2024)
Promega Corporation (PDF) (March 25, 2024)
Usona Institute, Inc. (PDF) (March 25, 2024)
Sharp Clinical Services, LLC (PDF) (March 25, 2024)
Final Order: Placement of 2-Methyl AP-237 in Schedule I (PDF) (March 15, 2024)
Mark Fenzl, D.O.; Decision and Order (PDF) (March 11, 2024)
DEA and HHS Joint Letter on Medications for Opioid Use Disorder (MOUD) (PDF) (March 8, 2024)
Update: DEA Response to Change Healthcare Cyberattack (PDF) (March 7, 2024)
AndersonBrecon Inc. dba PCI Pharma Services (PDF) (March 6, 2024)
Sigma Aldrich Company LLC (PDF) (March 6, 2024)
Sterling Pharma USA LLC (PDF) (March 6, 2024)
Stepan Company (PDF) (March 6, 2024)
Nusachi Labs, LLC (PDF) (March 6, 2024)
Benuvia Operations, LLC (PDF) (March 6, 2024)
Organic Consultants LLC DBA Cascade Chemistry (PDF) (March 6, 2024)
DEA Response to Change Healthcare Cyberattack (PDF) (March 1, 2024)
- REGISTRATION
- REPORTING
- RESOURCES
- CONTACT US
- PRIVACY NOTICE
- GET EMAIL UPDATES
Get Email Updates
The United States Department of Justice
You are now leaving a Department of Justice Web site.
You are about to access:
The Department of Justice does not endorse the organizations or views represented by this site and takes no responsibility for, and exercises no control over, the accuracy, accessibility, copyright or trademark compliance or legality of the material contained on this site.
Thank you for visiting our site.